Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody

Context Therapeutics Inc.

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.
Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.
Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).
Initial data for CT-95 Phase 1 trial expected in mid-2026.
CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.